Overview
Sonoma Biotherapeutics is a clinical-stage biotech company developing engineered regulatory T cell (Treg) therapies and effector T cell-modulating biologics to restore immune balance in autoimmune and inflammatory diseases. Their lead program, SBT-77-7101, is an autologous CAR-Treg therapy in Phase 1/1b for rheumatoid arthritis and hidradenitis suppurativa. The platform leverages proprietary manufacturing to isolate, expand, and enhance patient-derived Tregs for targeted immune modulation and potential disease cures.
Frequently asked questions
- What are Sonoma Biotherapeutics' key therapeutic programs?
- SBT-77-7101 is an autologous CAR-Treg therapy in Phase 1/1b for rheumatoid arthritis and hidradenitis suppurativa. SBT-11-5301 is a biologic that eliminates activated effector T cells, with Phase 1 completed in healthy volunteers and plans for combination trials.
- What is their Treg cell therapy platform?
- The platform engineers patient-derived Tregs through proprietary processes for selection, expansion, specificity, potency, stability, and persistence, aiming for one-time treatments that modulate immune responses and repair tissue in autoimmune diseases.
- What is the clinical and regulatory status of their pipeline?
- SBT-77-7101 is advancing in Phase 1/1b clinical trials. SBT-11-5301 has completed Phase 1 in healthy volunteers, with future combination studies planned. They partner with Regeneron on select Treg programs.